Seminars in Nuclear Medicine
Volume 34, Issue 1 , Pages 32-46 , January 2004

Imaging and therapy of tumors induced to express somatostatin receptor by gene transfer using radiolabeled peptides and single chain antibody constructs

  • Donald J Buchsbaum

      Affiliations

    • Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, AL, USA
    • Corresponding Author InformationAddress reprint requests to Donald J. Buchsbaum, PhD, Department of Radiation Oncology, University of Alabama at Birmingham, 1530 3rd Ave. South, WTI 674, Birmingham, AL 35294-6832, USA

References 

  1. Buchsbaum DJ, Langmuir VK, Wessels BW. Experimental radioimmunotherapy. Med Phys. 1993;20:551–567
  2. Buchsbaum DJ. Experimental radioimmunotherapy and methods to increase therapeutic efficacy. In:  Goldenberg DM editors. Cancer Therapy with Radiolabeled Antibodies. Boca Raton, FL: CRC Press; 1995;p. 115–140
  3. Knox SJ. Overview of studies on experimental radioimmunotherapy. Cancer Res. 1995;55(suppl):5832s–5836s
  4. Imam SK. Status of radioimmunotherapy in the new millennium. Cancer Biother Radiopharm. 2001;16:237–256
  5. Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med. 2002;43:693–713
  6. Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol. 2002;20:3545–3557
  7. Juweid ME. Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma (From clinical trials to clinical practice). J Nucl Med. 2002;43:1507–1529
  8. Vose JM, Wahl RL, Saleh M, et al.  Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2000;18:1316–1323
  9. Press OW, Eary JF, Gooley T, et al.  A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934–2942
  10. Kaminski MS, Zelenetz AD, Press OW, et al.  Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2001;19:3918–3928
  11. Wiseman GA, Gordon LI, Multani PS, et al.  Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia (A phase II multicenter trial). Blood. 2002;99:4336–4342
  12. Witzig TE, Gordon LI, Cabanillas F, et al.  Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–2463
  13. van Zanten-Przybysz I, Molthoff CF, Roos JC, et al.  Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. J Nucl Med. 2000;41:1168–1176
  14. Meredith RF, Alvarez RD, Partridge EE, et al.  Intraperitoneal radioimmunochemotherapy of ovarian cancer (A phase I study). Cancer Biother Radiopharm. 2001;16:305–315
  15. Alvarez RD, Huh WK, Khazaeli MB, et al.  A phase I study of combined modality 90Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin Cancer Res. 2002;8:2806–2811
  16. Hopkins K, Papanastassiou V, Kemshead JT. The treatment of patients with recurrent malignant gliomas with intratumoral radioimmunoconjugates. Recent Results Cancer Res. 1996;141:141–159
  17. Cokgor I, Akabani G, Kuan C-T, et al.  Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol. 2000;18:3862–3872
  18. Menda Y, Kahn D. Somatostatin receptor imaging of non-small cell lung cancer with 99mTc depreotide. Semin Nucl Med. 2002;32:92–96
  19. Warner RRP, O’Dorisio TM. Radiolabeled peptides in diagnosis and tumor imaging (Clinical overview). Semin Nucl Med. 2002;32:79–83
  20. Machac J, Krynyckyi B, Kim C. Peptide and antibody imaging in lung cancer. Semin Nucl Med. 2002;32:276–292
  21. Virgolini I, Kurtaran A, Raderer M, et al.  Vasoactive intestinal peptide receptor scintigraphy. J Nucl Med. 1995;36:1732–1739
  22. Lamberts SWJ, van der Lely AJ, de Herder WW, et al.  Octreotide. N Engl J Med. 1996;334:246–254
  23. Blum JE, Handmaker H, Rinne NA. The utility of a somatostatin-type receptor binding peptide radiopharmaceutical (P829) in the evaluation of solitary pulmonary nodules. Chest. 1999;115:224–232
  24. Traub T, Petkov V, Ofluoglu S, et al.  111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. J Nucl Med. 2001;42:1309–1315
  25. Zamora PO, Gulhke S, Bender H, et al.  Experimental radiotherapy of receptor-positive human prostate adenocarcinoma with 188Re-RC-160, a directly-radiolabeled somatostatin analogue. Int J Cancer. 1996;65:214–220
  26. Anderson CJ, Jones LA, Bass LA, et al.  Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. J Nucl Med. 1998;39:1944–1951
  27. Stolz B, Weckbecker G, Smith-Jones PM. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med. 1998;25:668–674
  28. de Jong M, Breeman WAP, Bernard BF, et al.  Tumor response after [90Y-DOTA0, Tyr3]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size. J Nucl Med. 2001;42:1841–1846
  29. Bugaj JE, Erion JL, Johnson MA, et al.  Radiotherapeutic efficacy of 153Sm-CMDTPA-Tyr3-octreotate in tumor-bearing rats. Nucl Med Biol. 2001;28:327–334
  30. Chinol M, Paganelli G, Zoboli S, et al.  90Y-DOTATOC treatment of patients with SSTr2 positive tumors (Preliminary results of phase I-II study). J Nucl Med. 1999;40:18P
  31. de Jong M, Krenning E. New advances in peptide receptor radionuclide therapy. J Nucl Med. 2002;43:617–620
  32. de Jong M, Valkema R, Jamar F, et al.  Somatostatin receptor-targeted radionuclide therapy of tumors (Preclinical and clinical findings). Semin Nucl Med. 2002;32:133–140
  33. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother. 1994;15:42–52
  34. Yokota T, Milenic DE, Whitlow M, et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992;52:3402–3408
  35. Vogel C-A, Bischof-Delaloye A, Mach JP, et al.  Direct comparison of a radioiodinated intact chimeric anti-CEA MAb with its F(ab′)2 fragment in nude mice bearing different human colon cancer xenografts. Br J Cancer. 1993;68:684–690
  36. Tai M-S, McCartney JE, Adams GP, et al.  Targeting c-erbB-2 expressing tumors using single-chain Fv monomers and dimers. Cancer Res. 1995;55(suppl):5983s–5989s
  37. Moffatt FL, Pinsky CM, Hammershaimb L, et al.  Clinical utility of external immunoscintigraphy with the IMMU-4 technetium-99m Fab’ antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum (Results of a pivotal, phase III trial). J Clin Oncol. 1996;14:2295–2305
  38. Fischman AJ, Babich JW, Strauss HW. A ticket to ride (Peptide radiopharmaceuticals). J Nucl Med. 1993;34:2253–2263
  39. Rowlinson G, Snook D, Busza A, et al.  Antibody-guided localization of intraperitoneal tumors following intraperitoneal or intravenous antibody administration. Cancer Res. 1987;47:6528–6531
  40. Zalutsky MR, Moseley RP, Benjamin JC, et al.  Monoclonal antibody and F(ab′)2 fragment delivery to tumor in patients with glioma (Comparison of intracarotid and intravenous administration). Cancer Res. 1990;50:4105–4110
  41. Quadri SM, Malik AB, Chu HB, et al.  Intraperitoneal indium-111- and yttrium-90-labeled human IgM (AC6C3-2B12) in nude mice bearing peritoneal carcinomatosis. J Nucl Med. 1996;37:1545–1551
  42. Kinuya S, Jeong JM, Garmestani K, et al.  Effect of metabolism on retention of indium-111-labeled monoclonal antibody in liver and blood. J Nucl Med. 1994;35:1851–1857
  43. Arano Y, Wakisaka K, Mukai T, et al.  Stability of a metabolizable ester bond in radioimmunoconjugates. Nucl Med Biol. 1996;23:129–136
  44. Rosenblum MG, Lamki LM, Murray JL, et al.  Interferon-induced changes in pharmacokinetics and tumor uptake of 111In-labeled antimelanoma antibody 96.5 in melanoma patients. J Natl Cancer Inst. 1988;80:160–165
  45. Kuhn JA, Wong JYC, Beatty BG. γ-Interferon enhancement of a multiple treatment regimen for radioimmunotherapy. Antibody Immunoconj Radiopharm. 1991;4:837–845
  46. Greiner JW, Ullmann CD, Nieroda C, et al.  Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with γ-interferon. Cancer Res. 1993;53:600–608
  47. Roselli M, Guadagni F, Buonomo O, et al.  Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen. J Clin Oncol. 1996;14:2031–2042
  48. Raben D, Buchsbaum DJ, Khazaeli MB, et al.  Enhancement of radiolabeled antibody binding and tumor localization through adenoviral transduction of the human carcinoembryonic antigen gene. Gene Ther. 1996;3:567–580
  49. Rogers BE, Rosenfeld ME, Khazaeli MB, et al.  Localization of iodine-125-mIP-Des-Met14-bombesin (7–13)NH2 in ovarian carcinoma induced to express the gastrin releasing peptide receptor by adenoviral vector-mediated gene transfer. J Nucl Med. 1997;38:1221–1229
  50. Rosenfeld ME, Rogers BE, Khazaeli MB, et al.  Adenoviral mediated delivery of gastrin releasing peptide receptor results in specific tumor localization of a bombesin analogue in vivo. Clin Cancer Res. 1997;3:1187–1194
  51. Rogers BE, Curiel DT, Mayo MS, et al.  Tumor localization of a radiolabeled bombesin analogue in mice bearing human ovarian tumors induced to express the gastrin releasing peptide receptor by an adenoviral vector. Cancer. 1997;80:2419–2424
  52. Clarke K, Lee FT, Brechbiel MW, et al.  Therapeutic efficacy of anti-Lewisy humanized 3S193 radioimmunotherapy in a breast cancer model (Enhanced activity when combined with taxol chemotherapy). Clin Cancer Res. 2000;6:3621–3628
  53. O’Donnell RT, DeNardo SJ, Miers LA, et al.  Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90Yttrium-DOTA-peptide-ChL6. Prostate. 2002;50:27–37
  54. Welt S, Ritter G, Williams C, et al.  Preliminary report of a phase I study of combination chemotherapy and humanized A33 antibody immunotherapy in patients with advanced colorectal cancer. Clin Cancer Res. 2003;9:1347–1353
  55. Kinuya S, Kawashima A, Yokoyama K, et al.  Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts. J Nucl Med. 2002;43:1084–1089
  56. Pedley RB, El-Emir E, Flynn AA, et al.  Synergy between vascular targeting agents and antibody-directed therapy. Int J Radiat Oncol Biol Phys. 2002;54:1524–1531
  57. Burke PA, DeNardo SJ, Miers LA, et al.  Cilengitide targeting of αvβ3 integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res. 2002;62:4263–4272
  58. Rogers BE, Garver RI, Grizzle WE, et al.  Genetic induction of antigens and receptors as targets for cancer radiotherapy. Tumor Targeting. 1998;3:122–137
  59. Rogers BE, Douglas JT, Sosnowski BA, et al.  Enhanced in vivo gene delivery to human ovarian cancer xenografts utilizing a tropism-modified adenovirus vector. Tumor Targeting. 1998;3:25–31
  60. Rogers BE, McLean SF, Kirkman RL, et al.  In vivo localization of [111In]-DTPA-D-Phe1-octreotide to human ovarian tumor xenografts induced to express the somatostatin receptor subtype 2 using an adenoviral vector. Clin Cancer Res. 1999;5:383–393
  61. Zinn KR, Chaudhuri TR. The type 2 human somatostatin receptor as a platform for reporter gene imaging. Eur J Nucl Med. 2002;29:388–399
  62. Rogers BE, Anderson CJ, Mayo MS, et al.  Localization of Cu-64-TETA-octreotide to human ovarian cancer xenografts induced to express SSTr2 with an adenoviral vector. J Nucl Med. 1998;39:63P
  63. Bonner, JA, Buchsbaum, DJ, Russo, SM, et al: A gene therapy-based approach for increasing tumor cell expression of epidermal growth factor receptor (EGFr). Semin Radiat Oncol (in press)
  64. Reubi JC, Schaer JC, Waser B, et al.  Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res. 1994;54:3455–3459
  65. Woltering EA, O’Dorisio MS, O’Dorisio TM. The role of radiolabeled somatostatin analogs in the management of cancer patients. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Principles and Practice of Oncology, PPO Updates, vol 9. (ed 4).. Philadelphia, PA: Lippincott-Raven; 1995;p. 1–16
  66. Reubi JC, Waser B, Schaer JC, et al.  Somatostatin receptors in human prostate and prostate cancer. J Clin Endocrinol Metab. 1995;80:2806–2814
  67. Nilsson S, Reubi JC, Kalkner KM, et al.  Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy. Cancer Res. 1995;55(suppl):5805s–5810s
  68. Halmos G, Schally AV, Sun B, et al.  High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. J Clin Endocrinol Metab. 2000;85:2564–2571
  69. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999;20:157–198
  70. Yamada Y, Post SR, Wang K, et al.  Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. Proc Natl Acad Sci U S A. 1992;89:251–255
  71. Hoyer D, Bell GI, Berelowitz M, et al.  Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci. 1995;16:86–88
  72. Feuerbach D, Fehlmann D, Nunn C, et al.  Cloning, expression and pharmacological characterisation of the mouse somatostatin sst(5) receptor. Neuropharmacology. 2000;39:1451–1462
  73. Virgolini I, Leimer M, Handmaker H, et al.  Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829. Cancer Res. 1998;58:1850–1859
  74. Reubi JC, Schar JC, Waser B, et al.  Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–282
  75. Schally AV. Oncological applications of somatostatin analogues. Cancer Res. 1988;48:6977–6985
  76. Bruns C, Weckbecker G, Raulf F, et al.  Molecular pharmacology of somatostatin-receptor subtypes. Ann N Y Acad Sci. 1994;733:138–146
  77. Buscail L, Saint-Laurent N, Chastre E, et al.  Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res. 1996;56:1823–1827
  78. Smith-Jones PM, Stolz B, Albert R, et al.  Synthesis, radiolabelling, and evaluation of DTPA/octreotide conjugates for radiotherapy. J Labelled Comp Radiopharm. 1995;37:499–501
  79. Stolz B, Smith-Jones P, Weckbecker G, et al.  Radiotherapy with yttrium-90 labeled DOTA-Tyr3-octreotide in tumor bearing rodents. J Nucl Med. 1997;38:18P
  80. Leimer M, Kurtaran A, Smith-Jones P, et al.  Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. J Nucl Med. 1998;39:2090–2094
  81. Paganelli G, Zoboli S, Cremonesi M, et al.  Receptor-mediated radionuclide therapy with 90Y-DOTA-D-Phe1-Tyr3-Octreotide (Preliminary report in cancer patients). Cancer Biother Radiopharm. 1999;14:477–483
  82. Mathieu I, Jamar F, Walrand S, et al.  Biodistribution of Y-86-DOTA-Tyr3-octreotide (SMT487) and renal protective effect of amino acid infusion (A phase I study). Eur J Nucl Med. 1998;25:837
  83. Smith MC, Liu J, Chen T, et al.  OctreoTher™ (Ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy). Digestion. 2000;62(suppl 1):69–72
  84. Valkema R, Kvols L, Jamar F, et al.  Phase I study of therapy with 90Y-SMT487 (octreother) in patients with somatostatin receptor (SS-R) positive tumors. J Nucl Med. 2002;5:33P
  85. Valkema R, Pauwels S, Kvols L, et al.  Peptide receptor radionuclide therapy (PRRT) with 90Y-DOTA0, Tyr3-octreotide (Y-Oc) and 111In-DTPA0-octreotide (In-Oc) (Comparison of tumor response and toxicity). J Nucl Med. 2002;5:34P
  86. Buscombe JR, Caplin ME, Bouvier C, et al.  Treating somatostatin receptor positive tumours with 90Y-lanreotide. J Nucl Med. 2002;5:34P
  87. Kwekkeboom DJ, Kam BL, Bakker WH, et al.  Treatment with 177Lu-DOTA-Tyr3-octreotate in patients with somatostatin receptor positive tumors. J Nucl Med. 2002;5:34P
  88. Freeman SM, Whartenby KA, Freeman JL, et al.  In situ use of suicide genes for cancer therapy. Semin Oncol. 1996;23:31–45
  89. Morris JC. Enzyme/prodrug-based tumor vaccination (All politics (and immunity) are local). J Natl Cancer Inst. 1999;91:1986–1989
  90. McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. J Natl Cancer Inst. 1996;88:1193–1203
  91. Danielson S, Kilstrup M, Barilla K, et al.  Characterization of the Escherichia coli codBA operon encoding cytosine permease and cytosine deaminase. Mol Microbiol. 1992;6:1335–1344
  92. Austin EA, Huber BE. A first step in the development of gene therapy for colorectal carcinoma (Cloning, sequencing, and expression of escherichia coli cytosine deaminase). Mol Pharmacol. 1993;43:380–387
  93. Hamstra DA, Rice DJ, Pu A, et al.  Combined radiation and enzyme/prodrug treatment for head and neck cancer in an orthotopic animal model. Radiation Res. 1999;152:499–507
  94. Hamstra DA, Rice DJ, Fahmy S, et al.  Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Ther. 1999;10:1993–2003
  95. Huber BE, Austin EA, Good SS, et al.  In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res. 1993;53:4619–4626
  96. Hirschowitz EA, Ohwada A, Pascal WR, et al.  In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Human Gene Ther. 1995;6:1055–1063
  97. Mullen C. Metabolic suicide genes in gene therapy. Pharmacol Ther. 1994;63:199–207
  98. Huber BE, Austin EA, Richards CA, et al.  Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with cytosine deaminase gene (Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase). Proc Natl Acad Sci U S A. 1994;91:8302–8306
  99. Dong Y, Wen P, Manome Y, et al.  In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Human Gene Ther. 1996;7:713–720
  100. DiMaio JM, Clary BM, Via DF, et al.  Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery. 1994;116:205–213
  101. Hanna NN, Mauceri HJ, Wayne JD, et al.  Virally directed cytosine deaminase/5-fluorocytosine gene therapy enhances radiation response in human cancer xenografts. Cancer Res. 1997;57:4205–4209
  102. Pederson LC, Buchsbaum DJ, Vickers SM, et al.  Molecular chemotherapy combined with radiation therapy enhances killing of cholangiocarcinoma cells in vitro and in vivo. Cancer Res. 1997;57:4325–4332
  103. Stackhouse MA, Pederson LC, Grizzle WE, et al.  Fractionated radiation therapy in combination with adenoviral delivery of the cytosine deaminase gene and 5-fluorocytosine enhances cytotoxic and antitumor effects in human colorectal and cholangiocarcinoma models. Gene Ther. 2000;7:1019–1026
  104. Khil MS, Kim JH, Mullen CA, et al.  Radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells in culture transduced with cytosine deaminease gene. Clin Cancer Res. 1996;2:53–57
  105. Gabel M, Kim JH, Kolozsvary A, et al.  Selective in vivo radiosensitization by 5-fluorocytosine of human colorectal carcinoma cells transduced with the E. coli cytosine deaminase (CD) gene. Int J Radiat Oncol Biol Phys. 1998;41:883–887
  106. Pederson LC, Vickers SM, Buchsbaum DJ, et al.  Combining cytosine deaminase expression, 5-fluorocytosine exposure, and radiotherapy increases cytotoxicity to cholangiocarcinoma cells. J Gastrointest Surg. 1998;2:283–291
  107. Pederson LC, Stackhouse, MA, Vickers, SM, et al: Redirection of cytosine deaminase gene transfer via basic fibroblast growth factor receptor enhances pancreatic carcinoma and cholangiocarcinoma cytotoxicity mediated by conversion of 5-fluorocytosine to 5-fluorouracil. Ann Surg (submitted)
  108. Ohwada A, Hirschowitz EA, Crystal RG. Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver. Hum Gene Ther. 1996;7:1567–1576
  109. Miller CR, Williams CR, Buchsbaum DJ, et al.  Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res. 2002;62:773–780
  110. Pandha HS, Martin LA, Rigg A, et al.  Genetic prodrug activation therapy for breast cancer (A phase I clinical trial of erbB-2-directed suicide gene expression). J Clin Oncol. 1999;17:2180–2189
  111. Breitling F, Dubel S, Seehaus T, et al.  A surface expression vector for antibody screening. Gene. 1991;104:147–153
  112. Fuchs P, Dubel S, Breitling F, et al.  Recombinant human monoclonal antibodies. Basic principles of the immune system transferred to E. coli. Cell Biophys. 1992;21:81–91
  113. Hu S-z, Shively L, Raubitschek A, et al.  Minibody (A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts). Cancer Res. 1996;56:3055–3061
  114. Holliger P, Prospero T, Winter G. “Diabodies” (Small bivalent and bispecific antibody fragments). Proc Natl Acad Sci U S A. 1993;90:6444–6448
  115. Wu AM, Williams LE, Zieran L, et al.  Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging. Tumor Targeting. 1999;4:47–58
  116. Yazaki PJ, Wu AM, Tsai SW, et al.  Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody (comparison to radioiodinated fragments). Bioconjug Chem. 2001;12:220–228
  117. Wu AM, Yazaki PJ, Tsai S, et al.  High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. Proc Natl Acad Sci U S A. 2000;97:8495–8500
  118. Adams GP, Schier R, McCall AM, et al.  High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001;61:4750–4755
  119. Buchsbaum DJ, Curiel DT. Gene therapy for the treatment of cancer. Cancer Biother Radiopharm. 2001;16:275–288
  120. Rogers BE, Zinn KR, Buchsbaum DJ. Gene transfer strategies for improving radiolabeled peptide imaging and therapy. Q J Nucl Med. 2000;44:208–223
  121. Rogers BE, Zinn KR, Lin C-Y, et al.  Targeted radiotherapy with [90Y]-SMT 487 in mice bearing human non-small cell lung tumor xenografts induced to express human somatostatin receptor subtype 2 with an adenoviral vector. Cancer. 2002;94:1298–1305
  122. Zinn KR, Buchsbaum DJ, Chaudhuri T, et al.  Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high affinity peptide radiolabeled with 99mTc or 188Re. J Nucl Med. 2000;41:887–895
  123. Manchanda R, Azure M, Lister-James J, et al.  Tumor regression in rat pancreatic (AR42J) tumor-bearing mice with Re-188 P2045—A somatostatin analog. Clin Cancer Res. 1999;5:3769s
  124. Chaudhuri TR, Rogers BE, Buchsbaum DJ, et al.  A noninvasive reporter system to image adenoviral-mediated gene transfer to ovarian cancer xenografts. Gynecol Oncol. 2001;83:432–438
  125. Zinn KR, Chaudhuri TR, Krasnykh VN, et al.  Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus. Radiology. 2002;223:417–425
  126. Chaudhuri TR, Krasnykh VN, Belousova N, et al.  An Ad-based strategy for imaging, radiotherapy, and enhanced tumor killing. Mol Ther. 2001;3:S25
  127. Liang Q, Gotts J, Satyamurthy N, et al.  Noninvasive, repetitive, quantitative measurement of gene expression from a bicistronic message by positron emission tomography, following gene transfer with adenovirus. Mol Ther. 2002;6:73–82
  128. Tjuvajev JG, Doubrovin M, Akhurst T, et al.  Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) for PET imaging of HSV1-tk gene expression. J Nucl Med. 2002;43:1072–1083
  129. Blasberg RG. Molecular imaging and cancer. Mol Cancer Ther. 2003;2:335–343

☆ This work was supported by DOE grant DE-FG05 93ER61654.

PII: S0001-2998(03)00071-0

doi: 10.1053/j.semnuclmed.2003.09.005

Seminars in Nuclear Medicine
Volume 34, Issue 1 , Pages 32-46 , January 2004

Article Tools

* Image Usage & Resolution